Vamil Divan
Stock Analyst at Guggenheim
(4.78)
# 117
Out of 5,050 analysts
238
Total ratings
66.47%
Success rate
20.85%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.60 | +404.20% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $219.16 | +10.42% | 28 | Oct 20, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $167 → $206 | $186.57 | +10.41% | 17 | Sep 23, 2025 | |
| SVRA Savara | Maintains: Buy | $8 → $11 | $3.95 | +178.48% | 2 | Sep 9, 2025 | |
| VALN Valneva SE | Maintains: Buy | $14 → $13 | $8.72 | +49.08% | 2 | Sep 8, 2025 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $86 → $114 | $90.43 | +26.06% | 12 | Sep 8, 2025 | |
| INSM Insmed | Maintains: Buy | $125 → $172 | $189.70 | -9.33% | 7 | Sep 8, 2025 | |
| ASMB Assembly Biosciences | Maintains: Buy | $31 → $39 | $31.20 | +25.00% | 2 | Sep 8, 2025 | |
| PROK ProKidney | Maintains: Buy | $6 → $7 | $2.89 | +142.21% | 2 | Jul 14, 2025 | |
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $9.19 | +52.34% | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $288 | $320.20 | -10.06% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $4.62 | +1,198.70% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $86.28 | +33.29% | 14 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $32.34 | +45.33% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $3.34 | +199.85% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $24.43 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $24.19 | +152.17% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $16.20 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $2.65 | +881.13% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.36 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $22.57 | -15.82% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $152.37 | -35.68% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $32.89 | +3.37% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.55 | +292.16% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $138.15 | -64.53% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $924.37 | -61.49% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $7.43 | -19.25% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $8.26 | +1,764.41% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $6.56 | +128.66% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $31.53 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $23.97 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $7.60 | +97.37% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $46.69 | +30.65% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.66 | +3,772.18% | 3 | Jan 17, 2018 |
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.60
Upside: +404.20%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $219.16
Upside: +10.42%
Johnson & Johnson
Sep 23, 2025
Upgrades: Buy
Price Target: $167 → $206
Current: $186.57
Upside: +10.41%
Savara
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $3.95
Upside: +178.48%
Valneva SE
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $8.72
Upside: +49.08%
ANI Pharmaceuticals
Sep 8, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $90.43
Upside: +26.06%
Insmed
Sep 8, 2025
Maintains: Buy
Price Target: $125 → $172
Current: $189.70
Upside: -9.33%
Assembly Biosciences
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $31.20
Upside: +25.00%
ProKidney
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $2.89
Upside: +142.21%
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $9.19
Upside: +52.34%
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $320.20
Upside: -10.06%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.62
Upside: +1,198.70%
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $86.28
Upside: +33.29%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $32.34
Upside: +45.33%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $3.34
Upside: +199.85%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $24.43
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $24.19
Upside: +152.17%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $16.20
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $2.65
Upside: +881.13%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $2.36
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $22.57
Upside: -15.82%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $152.37
Upside: -35.68%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $32.89
Upside: +3.37%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.55
Upside: +292.16%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $138.15
Upside: -64.53%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $924.37
Upside: -61.49%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $7.43
Upside: -19.25%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $8.26
Upside: +1,764.41%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $6.56
Upside: +128.66%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $31.53
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $23.97
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $7.60
Upside: +97.37%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $46.69
Upside: +30.65%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.66
Upside: +3,772.18%